N-[(2S)-2,3-dihydroxypropoxy]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide | 1609550-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[(2S)-2,3-dihydroxypropoxy]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
• CAS: 1609550-54-0
• 化学式: C₁₄H₁₄FIN₄O₄
• 分子量: 448.192
• InChiKey: MIYWBGNFRMYPAU-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  在 N-碘代丁二酰亚胺 、 三乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-[(2S)-2,3-dihydroxypropoxy]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors

  摘要：

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.086

文献信息

• Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors
  作者：Hejun Lu、Wangyang Tu、Hongbo Fei、Guoji Xu、Qiyue Hu、Lei Zhang、Bing Lin、Jijun Yuan、Junzhao Yin、Aishen Gong、Mimi Wan、Dan Wang、Xiaoyan Zhu、Jun Feng、Qian Wang、Piaoyang Sun

  DOI：10.1016/j.bmcl.2014.03.086

  日期：2014.6

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.